Evaluation of Pharmacokinetics and Tolerability of Eplerenone after Multiple Oral Doses of 100 mg in Healthy Korean Volunteers.
- Author:
SeongHae YOON
1
;
SeungHwan LEE
;
Dal Seok OH
;
Kyoung Soo LIM
;
Sang Goo SHIN
;
In Jin JANG
;
Kyung Sang YU
Author Information
1. Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital, Seoul, South Korea. ksyu@snu.ac.kr
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Eplerenone;
Aldosterone antagonist;
Pharmacokinetics;
Tolerability
- MeSH:
Administration, Oral;
Female;
Half-Life;
Heart Failure;
Humans;
Male;
Myocardial Infarction;
Receptors, Mineralocorticoid;
Spironolactone;
Ventricular Dysfunction, Left
- From:Journal of Korean Society for Clinical Pharmacology and Therapeutics
2011;19(2):84-90
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Eplerenone is a selective mineralocorticoid receptor antagonist which effectively blocks mineralocorticoid receptors in various tissues throughout the body. The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients post acute myocardial infarction complicated by left ventricular dysfunction and heart failure. The aim of this study was to evaluate pharmacokinetic characteristics and tolerability after multiple oral administration of eplerenone 100 mg for 7 days in healthy Korean volunteers. METHODS: A double-blind, randomized, placebo-controlled, parallel study was conducted in 22 healthy Korean subjects. Healthy males and females between age of 20 and 55 years were enrolled. Each subject received 100 mg eplerenone (N=16) or placebo (N=6) for 7 days. Blood samples for pharmacokinetic parameter determination on day 7 were collected pre-dose and up to 36 hours after last drug administration. Adverse events were reported throughout the treatment period. RESULTS: The steady-state concentration of eplerenone reached after multiple administration of eplerenone 100 mg for 7 days. The mean eplerenone Cmax of 1620.1 ng/mL was obtained at 1.0 hour (range 0.5 to 2 hours). The mean AUC0-24h,ss at day 7 was 8763.6 ng/mL*h. The mean oral clearance and mean terminal half-life of eplerenone were 13.0 L/h and 3.4 hours. There were some drug-related mild adverse events after eplerenone administration, but all adverse events recovered without any treatment. CONCLUSION: In this study, the pharmacokinetic parameters after multiple oral doses of eplerenone 100 mg for 7 days were evaluated and eplerenone at these doses were well tolerated in healthy Korean subjects.
